Concordance between Molecular and Phenotypic Testing of Mycobacterium tuberculosis Complex Isolates for Resistance to Rifampin and Isoniazid in the United States
Open Access
- 1 June 2014
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 52 (6), 1932-1937
- https://doi.org/10.1128/jcm.00417-14
Abstract
Multidrug-resistant (MDR) isolates of Mycobacterium tuberculosis complex (MTBC) are defined by resistance to at least rifampin (RMP) and isoniazid (INH). Rapid and accurate detection of multidrug resistance is essential for effective treatment and interruption of disease transmission of tuberculosis (TB). Overdiagnosis of MDR TB may result in treatment with second-line drugs that are more costly, less effective, and more poorly tolerated than first-line drugs. CDC offers rapid confirmation of MDR TB by the molecular detection of drug resistance (MDDR) for mutations associated with resistance to RMP and INH along with analysis for resistance to other first-line and second-line drugs. Simultaneously, CDC does growth-based phenotypic drug susceptibility testing (DST) by the indirect agar proportion method for a panel of first-line and second-line antituberculosis drugs. We reviewed discordance between molecular and phenotypic DST for INH and RMP for 285 isolates submitted as MTBC to CDC from September 2009 to February 2011. We compared CDC's results with those from the submitting public health laboratories (PHL). Concordances between molecular and phenotypic testing at CDC were 97.4% for RMP and 92.5% for INH resistance. Concordances between CDC's molecular testing and PHL DST results were 93.9% for RMP and 90.0% for INH. Overall concordance between CDC molecular and PHL DST results was 91.7% for RMP and INH collectively. Discordance was primarily attributable to the absence of known INH resistance mutations in isolates found to be INH resistant by DST and detection of mutations associated with low-level RMP resistance in isolates that were RMP susceptible by phenotypic DST. Both molecular and phenotypic test results should be considered for the diagnosis of MDR TB.Keywords
This publication has 10 references indexed in Scilit:
- Availability of an Assay for Detecting Mycobacterium tuberculosis, Including Rifampin-Resistant Strains, and Considerations for Its Use — United States, 20132013
- Rifampin Drug Resistance Tests for Tuberculosis: Challenging the Gold StandardJournal of Clinical Microbiology, 2013
- Rifampin Resistance Missed in Automated Liquid Culture System for Mycobacterium tuberculosis Isolates with Specific rpoB MutationsJournal of Clinical Microbiology, 2013
- Performance of Tuberculosis Drug Susceptibility Testing in U.S. Laboratories from 1994 to 2008Journal of Clinical Microbiology, 2012
- Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis [Short communication]The International Journal of Tuberculosis and Lung Disease, 2012
- Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosisThe International Journal of Tuberculosis and Lung Disease, 2012
- Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge [Short communication]The International Journal of Tuberculosis and Lung Disease, 2011
- Molecular Detection of Mutations Associated with First- and Second-Line Drug Resistance Compared with Conventional Drug Susceptibility Testing of Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2011
- Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test ResultsJournal of Clinical Microbiology, 2009
- American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of AmericaAmerican Journal of Respiratory and Critical Care Medicine, 2003